• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于质量源于设计理念的用于潜在治疗儿童耐多药结核病的贝达喹啉纳米乳剂的处方设计与优化

Formulation and optimisation of bedaquiline nanoemulsions for the potential treatment of multi drug resistant tuberculosis in paediatrics using quality by design.

作者信息

Ajayi Taiwo Oreoluwa, Poka Madan Sai, Witika Bwalya Angel

机构信息

Department of Pharmaceutical Science, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, 0204, South Africa.

出版信息

Sci Rep. 2024 Dec 30;14(1):31891. doi: 10.1038/s41598-024-83408-1.

DOI:10.1038/s41598-024-83408-1
PMID:39738619
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11686176/
Abstract

Bedaquiline is a drug used for the treatment of multidrug-resistant TB in adults and children that is currently only commercially available in tablet form. The present study was aimed at preparing nanoemulsion (NE) of BDQ using natural vegetable oils to deliver BDQ. The optimisation of surfactant mixtures was undertaken using Design of Experiments (DoE), specifically an optimal mixture design. The NEs were optimised while monitoring droplet size (DS), zeta potential (ZP), polydispersity index (PDI) and drug content (DC). The optimised NEs were further characterised using transmission electron microscopy, electrical conductivity, viscosity, pH and in vitro release studies. The optimised NE showed values of 191.6 nm ± 2.38 nm, 0.1176 ± 1.69, -25.9 mV ± 3.00 mV and 3.14 ± 0.82 mg/ml for DS, PDI, ZP and DC respectively. Furthermore, the TEM studies demonstrated the spherical shape of the optimised globules. The nanoemulsion was characterised by measuring its electrical conductivity, viscosity and pH which were determined as 53.1 µS/cm, 327 ± 3.05 cP and 5.63 ± 1.78, respectively. In conclusion, these NEs have great potential for improving solubility, drug delivery, and administration of BDQ. However, further studies are required to maximise the drug content and to demonstrate to what extent these NE have effect against MDR-TB.

摘要

贝达喹啉是一种用于治疗成人和儿童耐多药结核病的药物,目前仅以片剂形式在市场上销售。本研究旨在使用天然植物油制备贝达喹啉纳米乳剂(NE)以递送贝达喹啉。采用实验设计(DoE),特别是最优混合设计,对表面活性剂混合物进行优化。在监测液滴大小(DS)、zeta电位(ZP)、多分散指数(PDI)和药物含量(DC)的同时对纳米乳剂进行优化。使用透射电子显微镜、电导率、粘度、pH值和体外释放研究对优化后的纳米乳剂进行进一步表征。优化后的纳米乳剂的DS、PDI、ZP和DC值分别为191.6 nm±2.38 nm、0.1176±1.69、-25.9 mV±3.00 mV和3.14±0.82 mg/ml。此外,透射电子显微镜研究表明优化后的小球呈球形。通过测量纳米乳剂的电导率、粘度和pH值对其进行表征,结果分别为53.1 μS/cm、327±3.05 cP和5.63±1.78。总之,这些纳米乳剂在提高贝达喹啉的溶解度、药物递送和给药方面具有巨大潜力。然而,需要进一步研究以最大化药物含量,并证明这些纳米乳剂对耐多药结核病的作用程度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/e1dd53fd21f5/41598_2024_83408_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/284239e56a61/41598_2024_83408_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/71f84bed6ae2/41598_2024_83408_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/a69095417d2a/41598_2024_83408_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/66e43ba9d3f0/41598_2024_83408_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/ae7f35836201/41598_2024_83408_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/14550f68f644/41598_2024_83408_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/e8c463bb639f/41598_2024_83408_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/e1dd53fd21f5/41598_2024_83408_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/284239e56a61/41598_2024_83408_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/71f84bed6ae2/41598_2024_83408_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/a69095417d2a/41598_2024_83408_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/66e43ba9d3f0/41598_2024_83408_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/ae7f35836201/41598_2024_83408_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/14550f68f644/41598_2024_83408_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/e8c463bb639f/41598_2024_83408_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f41/11686176/e1dd53fd21f5/41598_2024_83408_Fig8_HTML.jpg

相似文献

1
Formulation and optimisation of bedaquiline nanoemulsions for the potential treatment of multi drug resistant tuberculosis in paediatrics using quality by design.基于质量源于设计理念的用于潜在治疗儿童耐多药结核病的贝达喹啉纳米乳剂的处方设计与优化
Sci Rep. 2024 Dec 30;14(1):31891. doi: 10.1038/s41598-024-83408-1.
2
Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.贝达喹啉三联吸入用粉末治疗耐药结核病。
Int J Pharm. 2019 Oct 30;570:118689. doi: 10.1016/j.ijpharm.2019.118689. Epub 2019 Sep 9.
3
A Quality by Design Approach for Optimizing Solid Lipid Nanoparticles of Bedaquiline for Improved Product Performance.采用质量源于设计理念优化贝达喹啉固体脂质纳米粒以改善产品性能。
AAPS PharmSciTech. 2024 Jul 1;25(6):152. doi: 10.1208/s12249-024-02873-z.
4
Development of Bedaquiline-Loaded SNEDDS Using Quality by Design (QbD) Approach to Improve Biopharmaceutical Attributes for the Management of Multidrug-Resistant Tuberculosis (MDR-TB).采用质量源于设计(QbD)方法开发载有贝达喹啉的自乳化药物传递系统(SNEDDS)以改善生物药剂学特性用于耐多药结核病(MDR-TB)的治疗
Antibiotics (Basel). 2023 Oct 3;12(10):1510. doi: 10.3390/antibiotics12101510.
5
Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.三重分枝杆菌ATP合酶突变阻碍贝达喹啉结合:原子和结构视角
Comput Biol Chem. 2020 Apr;85:107204. doi: 10.1016/j.compbiolchem.2020.107204. Epub 2020 Jan 13.
6
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.贝达喹啉和德拉马尼的叙述性综述:针对耐多药和广泛耐药结核分枝杆菌的新武器。
J Clin Lab Anal. 2024 Aug;38(15-16):e25091. doi: 10.1002/jcla.25091.
7
Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.贝达喹啉:一种用于耐多药结核病的新型二芳基喹啉。
Ann Pharmacother. 2014 Jan;48(1):107-15. doi: 10.1177/1060028013504087. Epub 2013 Nov 1.
8
Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.当前 ATP 合酶抑制剂在结核病治疗中的应用视角。
Curr Top Med Chem. 2021;21(18):1623-1643. doi: 10.2174/1568026621666210913122346.
9
Development of cannabidiol nanoemulsion for direct nose to brain delivery: statistical optimization,andevaluation.用于直接经鼻向脑递药的大麻二酚纳米乳的研制:统计优化及评价。
Biomed Mater. 2022 Sep 28;17(6). doi: 10.1088/1748-605X/ac9267.
10
Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.耐多药结核病患者中贝达喹啉联合优化背景治疗方案的早期治疗结局。
Indian J Tuberc. 2020 Apr;67(2):222-230. doi: 10.1016/j.ijtb.2020.03.002. Epub 2020 Mar 24.

本文引用的文献

1
Method development and validation of an analytical quality by design ultrafast liquid chromatographic method for the determination of bedaquiline from pharmaceutical bulk and nanoemulsions.采用分析质量设计的超快速液相色谱法开发和验证贝达喹啉药物原料和纳米乳剂的测定方法。
Biomed Chromatogr. 2024 Dec;38(12):e6037. doi: 10.1002/bmc.6037. Epub 2024 Nov 6.
2
Application of quality by design in optimization of nanoformulations: Principle, perspectives and practices.质量源于设计在纳米制剂优化中的应用:原理、前景与实践
Drug Deliv Transl Res. 2025 Mar;15(3):798-830. doi: 10.1007/s13346-024-01681-z. Epub 2024 Aug 10.
3
Development of bedaquiline nanoemulsions intended for paediatric multidrug-resistant tuberculosis: excipient selection and preformulation studies.
用于儿童耐多药结核病的贝达喹啉纳米乳剂的研发:辅料选择与处方前研究
Front Med Technol. 2024 Jun 10;6:1388113. doi: 10.3389/fmedt.2024.1388113. eCollection 2024.
4
A Quality by Design Approach for Developing SNEDDS Loaded with Vemurafenib for Enhanced Oral Bioavailability.一种载有维莫非尼的固体脂质纳米分散体的质量源于设计方法,用于提高口服生物利用度。
AAPS PharmSciTech. 2024 Jan 8;25(1):14. doi: 10.1208/s12249-023-02725-2.
5
Quality by design aided self-nano emulsifying drug delivery systems development for the oral delivery of Benidipine: Improvement of biopharmaceutical performance.质量源于设计辅助的自纳米乳化药物递送系统用于苯磺酸氨氯地平口服给药的开发:生物药剂学性能的改善
Drug Deliv. 2024 Dec;31(1):2288801. doi: 10.1080/10717544.2023.2288801. Epub 2023 Dec 11.
6
Quality by design approach-based fabrication and evaluation of self-nanoemulsifying drug delivery system for improved delivery of venetoclax.基于质量源于设计的方法制备和评价自微乳给药系统以改善 venetoclax 的递送
Drug Deliv Transl Res. 2024 May;14(5):1277-1300. doi: 10.1007/s13346-023-01462-0. Epub 2023 Nov 13.
7
Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs.纳米乳剂:一种用于提高药物生物利用度的新兴技术。
Scientifica (Cairo). 2023 Oct 28;2023:6640103. doi: 10.1155/2023/6640103. eCollection 2023.
8
Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC).载有贝达喹啉的固体脂质纳米粒在非小细胞肺癌(NSCLC)治疗中的药物递送
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1309. doi: 10.3390/ph16091309.
9
A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives.脂质体作为药物传递系统的综述:已批准产品的现状、监管环境和未来展望。
Molecules. 2022 Feb 17;27(4):1372. doi: 10.3390/molecules27041372.
10
Structural investigation and application of Tween 80-choline chloride self-assemblies as osmotic agent for water desalination.Tween 80-氯化胆碱自组装作为渗透剂用于海水淡化的结构研究与应用。
Sci Rep. 2021 Aug 23;11(1):17068. doi: 10.1038/s41598-021-96199-6.